ijms-logo

Journal Browser

Journal Browser

Cell and Molecular Perspectives in Breast Cancer

Special Issue Editor


E-Mail Website
Guest Editor
Mayo Clinic, Rochester, MN 55905, USA
Interests: tumorigenesis and cancer metastasis related to breast cancer; mechanism research; development of novel anticancer drugs; patient-tailored gene target therapy; correlation between breast cancer and other cancers; introduction of new treatments

Special Issue Information

Dear Colleagues,

In this Special Issue, we propose an approach centered around elucidating the mechanisms that underly tumorigenesis, anticancer drug resistance, and metastasis across diverse subtypes of breast cancer. This section encompasses analyses of protein interactions, genetic alterations, microenvironmental impacts, reactive oxygen species, and inflammatory processes. Breast cancer, arising from a collection of environmental and genetic perturbations, underscores the need for a comprehensive understanding of these intricate pathways in order to inform the development of novel therapeutics and robust biomarkers. Of particular interest is the phenomenon wherein breast cancer recurrence manifests as a more aggressive phenotype, characterized by diminished prognosis and heightened metastatic propensity. Our intent is to delve deeper into this aspect, employing both medical and fundamental scientific perspectives, with the objective of identifying strategies to ameliorate the burden of disease recurrence while enhancing women’s quality of life.

This Special Issue is open to original research articles, short communications, and reviews.

Dr. Seungbaek Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • molecular biology
  • cell biology
  • biomarker
  • novel therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 9743 KiB  
Article
Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via FOXA1 Inhibition
by Christine Song, Dawa Jung, Ayse Tuba Kendi, Jin Kyung Rho, Eun-Joo Kim, Ian Horn, Geoffry L. Curran, Sujala Ghattamaneni, Ji Yeon Shim, Pil Soo Kang, Daehun Kang, Jay B. Thakkar, Sannidhi Dewan, Val J. Lowe and Seung Baek Lee
Int. J. Mol. Sci. 2024, 25(13), 7494; https://doi.org/10.3390/ijms25137494 - 8 Jul 2024
Cited by 2 | Viewed by 2725
Abstract
Women with type 2 diabetes (T2D) have a higher risk of being diagnosed with breast cancer and have worse survival than non-diabetic women if they do develop breast cancer. However, more research is needed to elucidate the biological underpinnings of these relationships. Here, [...] Read more.
Women with type 2 diabetes (T2D) have a higher risk of being diagnosed with breast cancer and have worse survival than non-diabetic women if they do develop breast cancer. However, more research is needed to elucidate the biological underpinnings of these relationships. Here, we found that forkhead box A1 (FOXA1), a forkhead family transcription factor, and metformin (1,1-dimethylbiguanide hydrochloride), a medication used to treat T2D, may impact hormone-receptor-positive (HR+) breast cancer (BC) tumor cell growth and metastasis. Indeed, fourteen diabetes-associated genes are highly expressed in only three HR+ breast cancer cell lines but not the other subtypes utilizing a 53,805 gene database obtained from NCBI GEO. Among the diabetes-related genes, FOXA1, MTA3, PAK4, FGFR3, and KIF22 were highly expressed in HR+ breast cancer from 4032 breast cancer patient tissue samples using the Breast Cancer Gene Expression Omnibus. Notably, elevated FOXA1 expression correlated with poorer overall survival in patients with estrogen-receptor-positive/progesterone-receptor-positive (ER+/PR+) breast cancer. Furthermore, experiments demonstrated that loss of the FOXA1 gene inhibited tumor proliferation and invasion in vitro using MCF-7 and T47D HR+ breast cancer cell lines. Metformin, an anti-diabetic medication, significantly suppressed tumor cell growth in MCF-7 cells. Additionally, either metformin treatment or FOXA1 gene deletion enhanced tamoxifen-induced tumor growth inhibition in HR+ breast cancer cell lines within an ex vivo three-dimensional (3D) organoid model. Therefore, the diabetes-related medicine metformin and FOXA1 gene inhibition might be a new treatment for patients with HR+ breast cancer when combined with tamoxifen, an endocrine therapy. Full article
(This article belongs to the Special Issue Cell and Molecular Perspectives in Breast Cancer)
Show Figures

Figure 1

Back to TopTop